Skip to main content

Listen to your vagina. Ask for the BREX Rx

BREXAFEMME is the first and only medicine that doesn't just treat vaginal yeast, but kills it, with one-

day oral dosing.

YEAST INFECTION? SLAY IT

SHUT THAT
*ITCH DOWN

 

BREXAFEMME is…

  • different

    from all other medicines in how it attacks your vaginal yeast

  • fast

    with just one day of oral treatment that won’t disrupt your lifestyle

  • effective

    in quickly relieving the uncomfortable symptoms of your vaginal yeast infection

With BREXAFEMME, when your yeast infection is gone, it’s really gone.

Blister Pack
Not actual size

SO LONG, ITCHY, BURNING YEAST INFECTION

 
Peacesign

Start feeling
better within

2days*

*

Based on symptoms reported in patient diaries after taking
BREXAFEMME for 1 day.

Tattoo Woman

DOSING AS EASY AS 1, 2...

well, that’s it!

1-day treatment

Day

Take 2 tablets by
mouth in the morning

Night

Take 2 tablets by
mouth at night

If possible, the 2 doses (2 tablets each)
should be taken about 12 hours apart.

BREXAFEMME can be taken with or
without food.

 
1 Day

OTHER GOOD STUFF TO KNOW

PI

Patient Information

Get the important details
about BREXAFEMME,
including safety info and more.

Download
Brochure

Patient Brochure

Want even more info about
BREXAFEMME? Get it in our
patient brochure.

Download

Let’s talk
side effects

 

Take BREXAFEMME with confidence

If you have side effects, the most
common ones can include:

  • Loose stools
  • Nausea
  • Stomach pain
  • Dizziness
  • Vomiting

Most side effects are mild and don’t
last very long.

Man With Suitcase

CURE IT FOR LESS

CURE IT
FOR LESS

 

Redeem your Savings Card,
and you could pay as little as
$30

Card

3 ways to get a Savings Card:

  • Talk to your doctor about BREXAFEMME and receive a Savings Card
  • Visit BREXAFEMME.com/SAVINGS and print the BREXAFEMME Savings Card
  • Text “SAVE” to “BREXA” (27392) to instantly receive a mobile Savings Card

How to redeem your Savings Card:

  • Bring your prescription and BREXAFEMME Savings Card to the pharmacy
  • Commercially insured patients may pay as little as $30
  • Out-of-pocket patients may pay as little as $175
 
Chat

Want to know more?
Give us a call at
1-844-431-9894.

For terms and conditions, visit BREXAFEMME.com/SAVINGS.
Message and data rates may apply. 1 message per request. Reply “HELP” for help and “STOP” to stop.

Sign Up to Stay
Informed

 

If you want to get the latest and greatest info
about BREXAFEMME, click below. Together, we
can ditch the itch!

Woman With Child

What is BREXAFEMME?

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

How should I take BREXAFEMME?

Take BREXAFEMME exactly as your healthcare provider tells you to take it. Take BREXAFEMME tablets by mouth with or without food.

Important Safety Information:

Risk of Embryo-fetal Toxicity

  • BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies
  • For females of reproductive potential, verify that the patient is not pregnant prior to initiating BREXAFEMME treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
  • Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and, for 4 days after the last dose
  • BREXAFEMME is contraindicated in patients with a history of hypersensitivity to ibrexafungerp
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) of VVC were diarrhea, nausea, abdominal pain, dizziness, and vomiting. Most common adverse reactions observed in a clinical trial of RVVC were headache, abdominal pain, diarrhea, nausea, urinary tract infection and fatigue

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1‑888‑982‑SCYX (1‑888‑982‑7299) or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

  • You should not take BREXAFEMME if you are pregnant or could become pregnant. BREXAFEMME may harm your unborn baby. Tell your healthcare provider if you are pregnant, think you might be pregnant, or plan to be pregnant
  • If you can become pregnant, you may be asked by your healthcare provider to take a pregnancy test before taking BREXAFEMME and you should use effective birth control while taking BREXAFEMME and for 4 days after the last dose
  • You should not use BREXAFEMME if you are allergic to ibrexafungerp
  • It is not known if BREXAFEMME passes into your breast milk. If you are breastfeeding or plan to breastfeed, discuss with your healthcare provider if you should take BREXAFEMME or breastfeed
  • BREXAFEMME may affect the way other medicines work and other medicines may affect how BREXAFEMME works. Tell your healthcare provider about all the medicines you take
  • The most common side effects of BREXAFEMME include loose stools, nausea, stomach pain, dizziness, and vomiting

Call your doctor for medical advice about side effects. You may report side effects to SCYNEXIS, Inc.
at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Patient Information.

BREXAFEMME is a triterpenoid antifungal indicated for Treatment of VVC and Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult and post-menarchal pediatric females.

COLLAPSE EXPAND

Important Safety Information:

BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and for 4 days after the last dose.